After struggling to make recommendations about the product, an FDA panel rejects Hemispherx Biopharma's (HEB) chronic fatigue syndrome treatment Ampligen, saying it isn't ready for marketing. Several panel members struggled with their decisions because it appears the drug works in certain patients even if it wasn't strongly shown in the clinical data presented to the panel. Shares -20% AH.
From other sites
at CNBC.com (Mar 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs